IP Library Patent Application 13909957
Patent Application
App. No. 13/909,957

PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION AND PAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/909,957
Abstract

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ω-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ω-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Claims (23)

1 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of A, B, C, or D, or a pharmaceutically acceptable salt thereof:

2 . The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, or patches.

3 . The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil.

4 . The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.

5 . The pharmaceutical composition according to claim 4 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.

6 . The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets or capsules.

7 . A method of treating inflammation or pain, comprising the steps of:

identifying a subject suffering from inflammation or pain, and

administering to the subject the pharmaceutical composition of claim 1 , in an amount effective to treat inflammation or pain.

8 . The method according to claim 7 , wherein said method reduces or alleviates the symptoms of localized manifestations of inflammation characterized by acute or chronic swelling, pain, or redness.

9 . The method according to claim 7 , wherein said compound is administered by local administration or systemic administration.

10 . The method according to claim 7 , wherein said compound is administered by topical administration.

11 . The method according to claim 7 , wherein said inflammation and/or pain is associated with a skeletal or muscular disease or condition selected from the group consisting of: musculoskeletal sprains, musculoskeletal strains, tendonopathy, peripheral radiculopathy, osteoarthritis, degenerative joint disease, juvenile arthritis, gout, ankylosing spondylitis, psoriatic arthritis, system lupus erythematosus, costochondritis, tendonitis, bursitis, temporomandibular joint syndrome, and fibromyalgia.

12 . The method according to claim 7 , wherein said inflammation and/or pain is associated with joints, ligaments, tendons, bone, muscles, or fascia.

13 . The method according to claim 7 , wherein said inflammation and/or pain is associated with an inflammatory skin disease or disorder of dermatitis or psoriasis.

14 . The method according to claim 13 , wherein said dermatitis is atopic dermatitis or contact dermatitis.

15 . A method of treating an inflammatory skin disease or disorder, comprising the steps of:

identifying a subject in need thereof, and

administering to the pharmaceutical composition of claim 1 , in an amount effective to reduce or eliminate the symptoms of the inflammatory skin disease or disorder,

wherein the inflammatory skin disease or disorder is dermatitis, psoriasis, or acne.

16 . The method according to claim 15 , wherein said method treats atopic dermatitis and alleviates one or more symptoms selected from the group consisting of erythema, induration, lichenification, scaling, and oozing and crusting.

17 . The method according to claim 15 , wherein said method treats psoriasis and alleviates erythema, scaling, and/or thickness of the psoriasis lesions.

18 . The method according to claim 15 , wherein said method treats acne and alleviates acne lesions selected from the groups consisting of closed comedones, papules, pustules, nodules, and cysts.

Assignments (2)
CHANGE OF NAME Recorded Mar 18, 2016
From: OLATEC INDUSTRIES LLC
To: OLATEC THERAPEUTICS LLC
Reel/Frame 038177/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2013
From: ST. LAURENT, JOSEPH; JONES, GERALD S.; BRESSE, DAVID M.
To: OLATEC INDUSTRIES LLC
Reel/Frame 030762/0980 →